Skip to main content
SpringerLink
Log in

Ovarian cancer cell invasion is inhibited by paclitaxel

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Overproduction of matrix metalloproteinases (MMPs) and alterations in adhesive and migratory behavior are common characteristics of metastatic cancer cells. Ovarian cancer is a highly invasive type of malignancy. The effect of the antineoplastic drug paclitaxel on human ovarian cancer cell (Ovcar-3) invasion was studied using an in vitro invasion assay with reconstituted basement membrane. The effect of treatment with paclitaxel was also determined separately on certain invasion-associated events, such as the secretion of 72 kDa type IV collagenase (gelatinase A/MMP-2), the expression of the tissue inhibitor of metalloproteinase-2 (TIMP-2), cell attachment and migration. Ovcar-3 cell attachment, migration and in vitro invasion were significantly decreased after paclitaxel treatment (P=0.02, P<0.01 and P=0.001, respectively) whereas no alteration in the secretion of latent MMP-2 was noted. However, the intracellular localization of the immunoreactive protein for MMP-2 was altered in response to paclitaxel treatment. Interestingly, paclitaxel increased the appearance of TIMP-2 protein in culture medium (P=0.002) but did not change the expression of mRNA for TIMP-2 in Ovcar-3 cells. These data show that paclitaxel is an effective suppressor of Ovcar-3 cell invasion. It inhibits attachment and migratory activities of the cells but also causes a release of TIMP-2 protein into the tissue culture medium.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schiff PB, Fant J and Horwitz SB, 1979, Promotion of microtubular assembly in vitroby taxol. Nature, 277, 655-67.

    Google Scholar 

  2. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD and Goldberg GL, 1992, Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian carcinoma. J Clin Oncol, 10, 1748-53.

    Google Scholar 

  3. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong EK and Donehower RC, 1989, Taxol: unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med, 111, 273-79.

    Google Scholar 

  4. Thigpen T, Blessing J, Ball H, Hummel S and Barret R, 1990, Phase II trial of taxol as second-line therapy for ovarian carcinoma: a Gynecologic Oncology Group Study. Proc Am Assoc Clin Oncol, 10, 604.

    Google Scholar 

  5. Cottam DW and Rees RC, 1993, Regulation of matrix metalloproteinases: their role in tumor invasion and metastasis. Int J Oncol, 2, 861.

    Google Scholar 

  6. Khokha R and Denhardt DT, 1989, Matrix metalloproteinases and tissue inhibitor of metalloproteinases: a review of their role in tumorigenesis and tissue invasion. Invasion Metastasis, 9, 391-405.

    Google Scholar 

  7. Liotta LA, Steeg P and Stetler-Stevenson WG, 1991, Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-36.

    Google Scholar 

  8. Terranova VP, Hujanen ES, and Martin GK, 1986, Basement membrane and the invasive activity of metastatic tumor cells. J Natl Cancer Inst, 77, 311-16.

    Google Scholar 

  9. Liotta LA, Tryggvason K, Garbisa S, Hart I, Folts CM and Shafie S, 1980, Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature, 284, 67-8.

    Google Scholar 

  10. Nakajima M, Welch D, Belloni PN and Nicolson GL, 1987, Degradation of basement membrane (type IV) collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res, 47, 4869-76.

    Google Scholar 

  11. Seftor EA, Seftor RE and Hendrix MJ, 1990, Selection of invasive and metastatic subpopulations from heterogeneous human melanoma cell line. Biotechniques, 9, 324-31.

    Google Scholar 

  12. Terranova VP, Hujanen ES, Loeb DM, Martin GR, Thornburg L and Glushko V, 1986, Use of a reconstituted basement membrane to measure cell invasiveness and select for highly invasive tumor cells. Proc Natl Acad Sci USA, 83, 465-9.

    Google Scholar 

  13. Thorgeirsson UP, Turpeenniemi-Hujanen T, Williams JE, Heilman CA, Talmadge JE and Liotta LA, 1985, NIH/3T3 cells transfected with human tumor DNA containing activated rasoncogenes express they metastatic phenotype in nude mice. Mol Cell Biol, 5, 259-62.

    Google Scholar 

  14. Tryggvason K, Huhtala P, Höyhtyä M, Hujanen E and Hurskainen T, 1992, 70k type IV collagenase (gelatinase). Matrix,Suppl, 1, 45-50.

    Google Scholar 

  15. Turpeenniemi-Hujanen T, Thorgeirsson UP, Hart IR, Grant SG and Liotta LA, 1985, Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst, 75, 99-103.

    Google Scholar 

  16. Ura H, Bonfil D, Teich R, Reddel R, Pfeirfer A, Harris CC and Klein-Szanto AJP, 1989, Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive and metastatic abilities of oncogene-transformed human bronchial epithelial cells. Cancer Res, 49, 4615-21.

    Google Scholar 

  17. Autio-Harmainen H, Karttunen T and Hurskainen T, 1993, Expression of 72 kDa type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest, 63, 312-21.

    Google Scholar 

  18. Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG and Liotta LA, 1992, Evaluation of basement membrane components and the 72 kDa type IV collagenase in serious tumors of the ovary. Am J Surg Pathol, 16, 500-7.

    Google Scholar 

  19. Höyhtyä M, Fridman R, Komarek D, Porter-Jordan K, Stetler-Stevenson WG, Liotta LA and Liang C-M, 1994, Immunohistochemical localization of matrix metalloproteinases 2 and its specific inhibitor TIMP-2 in neoplastic tissue with monoclonal antibodies. Int J Cancer, 56, 500-5.

    Google Scholar 

  20. Naylor MS, Stamp GW, Davies BD and Balkwill FR, 1994, Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer, 58, 50-6.

    Google Scholar 

  21. Tryggvason K, Höyhtyä M and Pyke C, 1994, Type IV collagenase in invasive tumors. Breast Cancer Res Treat, 24, 209-18.

    Google Scholar 

  22. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE and Taylor SM, 1992, Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res, 52, 701-8.

    Google Scholar 

  23. Kleiner DE Jr, Tuuttila A, Tryggvason K and Stetler-Stevenson WG, 1993, Stability analysis of latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochem, 32, 1583-92.

    Google Scholar 

  24. Ponton A, Coulombe B and Skup D, 1991, Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. Cancer Res, 51, 2138-43.

    Google Scholar 

  25. Kleinman HK, McGarwey ML, Hassell JR, Star VL, Cannon FB, Laurie GW and Martin GR, 1986, Basement membrane complex with biological activity. Biochem, 28, 312-18.

    Google Scholar 

  26. Timpl R, Rohde H, Robey PG, Rennard SI, Foidart JM and Martin GR, 1979, A glycoprotein from basement membrane. J Biol Chem, 254, 9933-7.

    Google Scholar 

  27. Oi VT and Herzenberg LA, 1980, Immunglobulinproducing hybrid cell lines. In: Mishell BB and Shiigi SM, eds. Selected Methods in Cellular Immunology. San Francisco: Freeman, pp. 351-72.

    Google Scholar 

  28. Stetler-Stevenson WG, Krutzsch HC, Wacher MP, Margulies IMK and Liotta LA, 1989, The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation. J Biol Chem, 264, 1353-6.

    Google Scholar 

  29. Fridman R, Fuerst TR, Bird RE, Höyhyä M, Oelkuct M, Kraus S, Komarek D, Liotta LA, Berkan ML and Stetler-Stevenson WG, 1992, Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. J Biol Chem, 267, 15398-405.

    Google Scholar 

  30. Heussen C and Dowdle ED, 1980, Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem, 102, 192-202.

    Google Scholar 

  31. Murphy G, Ward RC, Hembry RM, Reynolds JJ, Kühn K and Tryggvason K, 1989, Characterization of gelatinase from pig polymorphonuclear leucocytes. Biochem J, 258, 463-72.

    Google Scholar 

  32. Hujanen ES and Turpeenniemi-Hujanen, 1991, Recombinant interferon alpha and gamma modulate the invasive potential of human melanoma in vitro. Int J Cancer, 47, 576-81.

    Google Scholar 

  33. Klebe RJ, 1974, Isolation of a collagen-dependent cell attachment factor. Nature, 250, 248-51.

    Google Scholar 

  34. Hujanen E and Terranova VP, 1985, Migration of tumor cells to organ-derived chemoattractants. Cancer Res, 45, 3517-21.

    Google Scholar 

  35. Chomczynski P and Sacchi N, 1987, Single step method of RNA isolation by acid guanidium thiocyanate phenol chloroform extraction. Anal Biochem, 162, 156-9.

    Google Scholar 

  36. Devreotes PN and Zigmond SH, 1988, Chemotaxis in eukaryotic cells: a focus on leukocytes and Dictyostelium. Annu Rev Cell Biol, 4, 649-86.

    Google Scholar 

  37. Davies B, Brown PD, East N, Crimmin MJ and Balkwill FR, 1993, A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian cancer xenografts. Cancer Res, 53, 2087-91.

    Google Scholar 

  38. Matrisian LM, 1990, Metalloproteinases and their inhibitors in matrix remodelling. Trends Genet, 6, 121-5.

    Google Scholar 

  39. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA and Goldberg GI, 1995, Mechanism of cell surface activation of 72-kDa type IV collagenase. J Biol Chem, 270, 5331-8.

    Google Scholar 

  40. Monsky WL, Kelly T, Lin C-Y, Yeh Y, Stetler-Stevenson WG, Mueller SC and Chen W-T, 1993, Binding and localization of Mr 72,000 matrix metalloproteinase at cell surface invadopodia. Cancer Res, 53, 3159-64.

    Google Scholar 

  41. Hujanen ES, Väisänen A, Zheng A, Tryggvason K and Turpeenniemi-Hujanen T, 1994, Regulation of 72-kd and 92-kd type IV collagenase (gelatinase A and B) gene expression by interferon alpha and gamma in human melanoma. Int J Cancer, 58, 582-6.

    Google Scholar 

  42. Höyhtyä M, Hujanen ES, Turpeenniemi-Hujanen T, Thorgeirsson U, Liotta LA and Tryggvason K, 1990, Modulation of type IV collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitroby monoclonal antibodies to type IV collagenase. Int J Cancer, 46, 282-6.

    Google Scholar 

  43. Stearns ME and Wang M, 1992, Taxol blocks processes essential for prostate tumor cell (PC-2 ML) invasion and metastases. Cancer Res, 52, 3776-81.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and Radiotherapy, University Hospital of Oulu, Oulu, Finland

    Anna Westerlund  & Taina Turpeenniemi-Hujanen

  2. Institute of Dentistry, University of Oulu, Oulu, Finland

    Erkki Hujanen

  3. Diabor LTD, Oulu, Finland

    Matti Höyhtyä

  4. Department of Obstetrics and Gynecology, University Hospital of Oulu, Oulu, Finland

    Ulla Puistola

Authors
  1. Anna Westerlund
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erkki Hujanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matti Höyhtyä
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ulla Puistola
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Taina Turpeenniemi-Hujanen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Westerlund , A., Hujanen , E., Höyhtyä , M. et al. Ovarian cancer cell invasion is inhibited by paclitaxel. Clin Exp Metastasis 15, 318–328 (1997). https://doi.org/10.1023/A:1018481617275

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018481617275

Search

Navigation